JP2022137047A5 - - Google Patents

Download PDF

Info

Publication number
JP2022137047A5
JP2022137047A5 JP2022096439A JP2022096439A JP2022137047A5 JP 2022137047 A5 JP2022137047 A5 JP 2022137047A5 JP 2022096439 A JP2022096439 A JP 2022096439A JP 2022096439 A JP2022096439 A JP 2022096439A JP 2022137047 A5 JP2022137047 A5 JP 2022137047A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
alkyl
acceptable salt
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022096439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022137047A (ja
Filing date
Publication date
Priority claimed from JP2019531160A external-priority patent/JP7091336B2/ja
Application filed filed Critical
Publication of JP2022137047A publication Critical patent/JP2022137047A/ja
Publication of JP2022137047A5 publication Critical patent/JP2022137047A5/ja
Pending legal-status Critical Current

Links

JP2022096439A 2016-12-22 2022-06-15 ヒストンメチルトランスフェラーゼ阻害剤 Pending JP2022137047A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662438121P 2016-12-22 2016-12-22
US62/438,121 2016-12-22
JP2019531160A JP7091336B2 (ja) 2016-12-22 2017-12-21 ヒストンメチルトランスフェラーゼ阻害剤
PCT/US2017/067855 WO2018119208A1 (en) 2016-12-22 2017-12-21 Histone methyltransferase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019531160A Division JP7091336B2 (ja) 2016-12-22 2017-12-21 ヒストンメチルトランスフェラーゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2022137047A JP2022137047A (ja) 2022-09-21
JP2022137047A5 true JP2022137047A5 (enExample) 2023-03-20

Family

ID=60972497

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531160A Expired - Fee Related JP7091336B2 (ja) 2016-12-22 2017-12-21 ヒストンメチルトランスフェラーゼ阻害剤
JP2022096439A Pending JP2022137047A (ja) 2016-12-22 2022-06-15 ヒストンメチルトランスフェラーゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019531160A Expired - Fee Related JP7091336B2 (ja) 2016-12-22 2017-12-21 ヒストンメチルトランスフェラーゼ阻害剤

Country Status (7)

Country Link
US (2) US10829452B2 (enExample)
EP (2) EP3558971B1 (enExample)
JP (2) JP7091336B2 (enExample)
AR (1) AR110443A1 (enExample)
ES (2) ES2981507T3 (enExample)
TW (1) TW201829386A (enExample)
WO (1) WO2018119208A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558971B1 (en) * 2016-12-22 2022-02-23 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
CN118021814A (zh) 2017-04-21 2024-05-14 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
US20210260040A1 (en) * 2017-10-18 2021-08-26 Epizyme, Inc. Methods of using ehmt2 inhibitors in treating or preventing blood disorders
JP2021500327A (ja) * 2017-10-18 2021-01-07 エピザイム,インコーポレイティド 免疫療法にehmt2阻害剤を使用する方法
CN112105796B (zh) 2018-03-09 2024-10-25 斯伦贝谢技术有限公司 集成井施工系统操作
CN111196817B (zh) * 2018-11-19 2021-06-11 四川大学华西医院 作为brpf1抑制剂的三环化合物
WO2020168927A1 (zh) * 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
CN111620818B (zh) * 2019-02-28 2023-09-29 暨南大学 8,9-二甲氧基啡啶类化合物及其应用
CN116710431A (zh) * 2020-11-19 2023-09-05 泰洛治疗公司 小分子化合物和组合物
WO2022115377A1 (en) * 2020-11-24 2022-06-02 Amgen Inc. Tricyclic carboxamide derivatives as prmt5 inhibitors
EP4284781A1 (en) 2021-01-27 2023-12-06 Vandria SA Urolithin derivatives and methods of use thereof
CN113004294B (zh) * 2021-03-08 2023-01-17 温州大学新材料与产业技术研究院 一种四氢呋喃并1,4-二氢喹啉类化合物及其制备方法和应用
CN114573569B (zh) * 2022-03-30 2023-07-04 邦恩泰(山东)生物医药科技集团股份有限公司 一种异喹啉类化合物的制备方法
CN117903150A (zh) * 2024-01-11 2024-04-19 中国科学技术大学 一种烯基取代的多环氮杂环的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
KR100826817B1 (ko) 2000-03-15 2008-05-02 사노피-아벤티스 도이칠란트 게엠베하 치환된 베타-카볼린
CA2510375A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
ES2406730T3 (es) * 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
EP1846419B1 (en) 2005-02-09 2014-04-16 3M Innovative Properties Company Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines
CA2974246C (en) * 2006-09-01 2020-02-25 Senhwa Biosciences, Inc. Tricyclic heteroaryl compounds and their use as protein modulators
WO2008101682A2 (en) 2007-02-22 2008-08-28 Syngenta Participations Ag Iminipyridine derivatives and their uses as microbiocides
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
EA018068B1 (ru) 2008-03-03 2013-05-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности tlr
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010056038A2 (ko) * 2008-11-11 2010-05-20 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
EP2485731B1 (en) 2009-10-06 2016-05-11 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as pdk1 inhibitors
US20130231360A1 (en) 2010-04-22 2013-09-05 The Brigham And Women S Hospital, Inc. Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases
JP2013533239A (ja) 2010-06-25 2013-08-22 ファキュルテ ユニヴェルシテール ノートル−ダム ド ラ ペ 増殖性疾患の治療に有用なβカルボリン誘導体
PT2688887E (pt) 2011-03-23 2015-07-06 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
KR101827444B1 (ko) 2012-02-01 2018-02-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
US10662193B2 (en) 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
US9284272B2 (en) * 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
DK3154957T3 (da) * 2014-06-16 2020-02-17 Fundacion Para La Investig Medica Aplicada Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
CN108431000A (zh) * 2015-11-16 2018-08-21 基础应用医学研究基金会 作为dna甲基转移酶抑制剂的新型化合物
EP3558971B1 (en) * 2016-12-22 2022-02-23 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors

Similar Documents

Publication Publication Date Title
JP2022137047A5 (enExample)
CA3081983A1 (en) Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
US9643977B2 (en) Necroptosis inhibitors and methods of use therefor
KR102543559B1 (ko) 설폰아미드화합물 또는 이의 염
JP2019031560A5 (enExample)
JP2020504716A5 (enExample)
CA2950072C (en) Novel pyrrolidine compound and application as melanocortin receptor agonist
JP2021502403A5 (enExample)
JP2004531490A5 (enExample)
JP2017510642A5 (enExample)
CA2668997A1 (en) 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
JP2012500805A5 (enExample)
JP2018522032A5 (enExample)
JP2007519659A5 (enExample)
JP2019524883A5 (enExample)
JP2019513743A (ja) インドールアミン 2,3−ジオキシゲナーゼ阻害剤、その製造方法及び応用
CN118119618A (zh) 一种杂芳环类化合物及其应用
JP2009534406A5 (enExample)
JP2017510643A5 (enExample)
JP2019532974A5 (enExample)
JP2020505356A5 (enExample)
TWI585087B (zh) Novel tetrahydropyridine pyrimidine compounds or salts thereof
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用
JP2016503785A5 (enExample)
JP2021501208A5 (enExample)